Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (Q34246882)

31 July 2017

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (English)

1 reference

31 July 2017

0 references

0 references

chronic heart failure

1 reference

inferred from title

author

Christopher B. Granger

3

object named as

Christopher B Granger

1 reference

31 July 2017

2

Karl Swedberg

1 reference

31 July 2017

9

Salim Yusuf

1 reference

31 July 2017

5

John J V McMurray

1 reference

31 July 2017

1

Marc A Pfeffer

1 reference

CHARM Investigators and Committees

31 July 2017

11

object named as

CHARM Investigators and Committees

1 reference

31 July 2017

6

Eric L Michelson

1 reference

31 July 2017

4

Peter Held

1 reference

31 July 2017

Bertil Olofsson

7

1 reference

31 July 2017

Jan Ostergren

8

1 reference

31 July 2017

Stuart Pocock

10

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

31 July 2017

1 reference

31 July 2017

362

1 reference

31 July 2017

759-766

1 reference

31 July 2017

9386

1 reference

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Long-Term Trends in the Incidence of and Survival with Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Heart failure and the aging population: an increasing burden in the 21st century?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Heart failure--an epidemic of uncertain proportions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

1 reference

7 January 2021

Angiotensin receptors and their antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) pro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Neurohormonal blockade in chronic heart failure. How much is enough? Can there be too much?.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914282-1

7 January 2021

10.1016/S0140-6736(03)14282-1

Identifiers

DOI

1 reference

31 July 2017

1 reference